Scholar Rock Holding Corp

NASDAQ:SRRK   3:59:57 PM EDT
57.62
-0.43 (-0.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.94B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.76 Million
Adjusted EPS-$0.57
See more estimates
10-Day MA$52.32
50-Day MA$46.55
200-Day MA$24.22
See more pivots

Scholar Rock Holding Corp Stock, NASDAQ:SRRK

620 MEMORIAL DRIVE, 2ND FLOOR, CAMBRIDGE, MA 02139
United States of America
Phone: 857-259-3860
Number of Employees: 65

Description

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.